Melanotan II

Most common during the first 3-7 days of use or with higher doses. Typically resolves with continued use (tachyphylaxis). Injecting in the evening and taking with food may reduce severity. Antiemetics (e.g., ondansetron) can be used if severe.

Transient redness and warmth of the face, often occurring 30-60 minutes after injection. Usually resolves within 1-2 hours. More pronounced with higher doses or rapid dose escalation.

Reported by many users, particularly males. This is a direct effect of melanocortin receptor activation in sexual function centers. Not considered adverse by most users but should be noted for informed consent.

Many users report reduced appetite and modest weight loss. This is mediated by MC4R activation in the hypothalamus. Ensure adequate caloric and nutrient intake, especially if using for extended periods.

Pre-existing pigmented lesions darken along with normal skin. This is expected and typically reverses after discontinuation. Users with numerous or atypical moles should consult a dermatologist before use.

Mild to moderate headaches reported in some users, typically early in treatment. Usually self-resolving. Ensure adequate hydration.

May occur shortly after injection, particularly with rapid dose escalation. Sit or lie down if this occurs. Usually resolves within 30 minutes.

Reported primarily in male users, especially at higher doses. Related to melanocortin receptor activation in sexual function pathways. May be unwanted in certain contexts.

Localized erythema, itching, or mild pain at the injection site. Usually mild and self-resolving. Proper injection technique and site rotation minimize risk.

Darkening of sensitive areas due to high melanocyte density. Typically reversible after discontinuation but may take weeks to months.

More severe nausea with actual vomiting occurs in a subset of users, particularly with rapid dose escalation or higher doses. Slow titration and evening dosing reduce risk. Antiemetics may be necessary.

Melanocortin receptors regulate vascular tone; some users report elevated blood pressure. Monitor blood pressure regularly, especially if using higher doses or for extended periods. Discontinue if significant elevation occurs.

Theoretical risk due to melanocyte stimulation and potential for malignant transformation in susceptible individuals. Users with personal or family history of melanoma, atypical moles, or xeroderma pigmentosum should avoid use. Regular dermatological monitoring is essential for all users.

Melanotan II is not approved for human use, and long-term safety data in humans are limited. Melanocyte stimulation theoretically increases melanoma risk, particularly in genetically predisposed individuals. This remains a major safety concern. Users must understand this risk and undergo regular dermatological screening.

Anaphylaxis or severe allergic reactions are rare but possible. Symptoms include difficulty breathing, swelling of face/throat, severe rash, or rapid heartbeat. Seek emergency medical attention immediately if these occur.